香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 執行董事 林賢雅 香 港，二 零 二 五 年 八 月 十 八 日 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 董事會會議日期 華 檢 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）謹 此 宣 佈， 本 公 司 將 於 二 零 二 五 年 八 月 二 十 九 日（星 期 五）舉 行 本 公 司 董 事 會（「董事會」) 會 議，以（其 中 包 括）考 慮 及 批 准 本 集 團 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 中 期 業 績，派 付 中 期 股 息（如 有），以 及 處 理 任 何 其 他 事 項。 承董事會命 華檢醫療控股有限公司 於 本 公 告 日 期，董 事 會 由 三 名 ...

Core Viewpoint - The company, Huajian Medical (1931.HK), has proposed to seek shareholder approval for a purchase authorization to invest in cryptocurrencies, particularly Ethereum (ETH), as part of its asset allocation strategy and business development plans [1] Group 1: Company Actions - The company's board believes that purchasing and holding cryptocurrencies is a crucial step in solidifying its Ethereum reserves and accelerating the development of the ivd.xyz exchange ecosystem [1] - The board has recommended that shareholders approve a resolution allowing the company to potentially purchase cryptocurrencies over a period of 36 months, with a total purchase limit not exceeding 3 billion HKD [1] Group 2: Strategic Alignment - The potential cryptocurrency purchases and the authorization for such purchases are considered to align with the company's long-term development strategy and the overall interests of its shareholders [1]

Core Viewpoint - Xinhua Medical (600587) is focusing on its core businesses in medical devices and pharmaceutical equipment, indicating that the strategic transformation of its subsidiary, Huajian Medical (01931), will not impact the overall strategic positioning of Xinhua Medical [1] Group 1 - Xinhua Medical has received inquiries regarding the specific measures to support the strategic transformation of its subsidiary, Huajian Medical [1] - The company has emphasized that the future development strategy and vision for Huajian Medical will be announced through relevant announcements [1] - The strategic transformation of Huajian Medical is not expected to affect the overall strategy of Xinhua Medical [1]

Group 1 - The core point of the article is that Xinhua Medical holds a significant stake in Huajian Medical, which has recently seen a rise in its operations related to stablecoins, potentially benefiting Xinhua Medical's investment returns [1] - Xinhua Medical owns 443.7 million shares of Huajian Medical, representing a 27.29% ownership stake [1] - The financial performance of Huajian Medical will impact Xinhua Medical's investment income due to the equity method of accounting used for this subsidiary [1]

Group 1 - The core point of the article is the relationship between Xinhua Medical and its subsidiary Huajian Medical, specifically regarding ownership and support for business development [1] - Xinhua Medical holds a 27.29% stake in Huajian Medical through its wholly-owned subsidiary Huatuo International Development Co., Ltd [1] - The company respects Huajian Medical's independent decision-making based on its own development strategy and market judgment as a minority shareholder [1] Group 2 - Xinhua Medical will continue to monitor the risks and opportunities in the industry where Huajian Medical operates [1]

Group 1 - The core point of the article is that Xinhua Medical holds a significant stake in Huajian Medical, which has recently seen a rise in its operations related to stablecoins, potentially benefiting Xinhua Medical [1] - Xinhua Medical owns 443.7 million shares of Huajian Medical, representing a 27.29% ownership stake [1] - The company uses the equity method to account for its investment in Huajian Medical, meaning that changes in Huajian Medical's net profit will directly impact Xinhua Medical's investment income [1]

Core Viewpoint - Xinhua Medical (600587) holds a significant stake in Huajian Medical, which has recently engaged in a strategic partnership with HashKey Exchange to purchase Ethereum, potentially impacting Xinhua Medical's profitability through increased investment income from Huajian Medical's net profit [1] Group 1 - Xinhua Medical indirectly holds 443.7 million shares of Huajian Medical, representing a 27.29% stake [1] - Huajian Medical has established a strategic cooperation with HashKey Exchange, purchasing approximately HKD 149 million worth of Ethereum through its OTC services [1] - As of August 11, Huajian Medical's market capitalization reached HKD 15 billion, valuing Xinhua Medical's stake at HKD 4.1 billion [1] Group 2 - Xinhua Medical states that Huajian Medical is an important associate company, and its net profit will influence Xinhua Medical's investment income through equity method accounting [1]

转自：智通财经 【新华医疗：华检医疗推进医疗创新药RWA交易所生态】智通财经8月18日电，新华医疗在互动平台表 示，华检医疗推进的医疗创新药RWA交易所生态及配套稳定币体系，为业务拓展提供了新的发展思 路，公司未来将持续关注华检医疗所处行业的风险与机遇。 ...

Core Viewpoint - Company plans to apply for a funding limit of up to 3 billion HKD for potential cryptocurrency purchases, aiming to enhance its "Global Enhanced Ethereum (ETH) Treasury" strategy and accelerate the tokenization ecosystem of medical innovation drug intellectual property [1] Group 1: Strategic Upgrade - The board previously approved a maximum of 880 million HKD for purchasing Ethereum as a strategic reserve, with the first batch of 5,190 ETH acquired for a total price of 149 million HKD at an average cost of approximately 28,798 HKD (3,661 USD) per unit [1] - The new announcement seeks to increase the funding limit to 3 billion HKD, positioning the company as a leader in Ethereum reserves among listed companies in Hong Kong and globally [1] - The company emphasizes that the acquisition plan will strictly adhere to the regulatory framework for virtual assets in Hong Kong, ensuring asset safety and liquidity through compliant channels [1] Group 2: Ecological Synergy - The cryptocurrency strategy is closely tied to the company's core business of tokenizing medical innovation drug assets (RWA), utilizing its self-developed Web3 exchange ivd.xyz to convert high-value medical assets into tradable digital certificates [2] - Ethereum serves as the underlying infrastructure, providing value anchoring for RWA and generating staking income to support the treasury's growth [2] - The company has implemented a "seven-layer downside protection mechanism" and a "three-tier income enhancement engine" to safeguard shareholder interests amid market volatility [2] Group 3: Market Response - Following the announcement of the first ETH purchase, the company's stock price surged over 91% within a month, with a market capitalization exceeding 15 billion HKD, making it a focal point in the Hong Kong medical sector [3] - Market analysis indicates that the company's dual-driven model of "crypto treasury + medical RWA" aligns with valuation logic seen in leading Ethereum companies in the US, while offering greater industrial synergy [3] - The company has established a strategic partnership with BGI Win-Win Fund to acquire quality innovative drug pipelines, further enhancing the asset base of the ivd.xyz exchange [3] Group 4: Compliance First - The company reiterated that all cryptocurrency transactions will be conducted exclusively on regulated platforms, seeking independent approval at the shareholder special meeting to ensure transparency [3] - If the 3 billion HKD application is approved, the authorization will be valid for 36 months, allowing the board to execute the purchase plan in phases based on market conditions [3] - As traditional medical companies explore digital transformation, the company's innovative model of "Ethereum treasury + medical RWA" opens new pathways for asset allocation and value reassessment in the industry [3]

Core Viewpoint - Company plans to apply for a funding limit of up to 3 billion HKD for potential cryptocurrency purchases, aiming to enhance its "Global Enhanced Ethereum (ETH) Treasury" strategy and accelerate the tokenization ecosystem of medical innovation drug intellectual property [1] Group 1: Strategic Upgrade - The board previously approved a maximum of 880 million HKD for purchasing Ethereum as a strategic reserve, with the first batch of 5,190 ETH acquired for a total price of 149 million HKD at an average cost of approximately 28,798 HKD (3,661 USD) per ETH [2] - The new announcement seeks to increase the funding limit to 3 billion HKD, positioning the company as a leader in Ethereum reserves among listed companies in Hong Kong and globally [2] - The company emphasizes adherence to the regulatory framework for virtual assets in Hong Kong, ensuring asset safety and liquidity through compliant channels [2] Group 2: Ecological Synergy - The cryptocurrency strategy is closely tied to the company's core business of tokenizing medical innovation drug assets, utilizing its self-developed Web3 exchange ivd.xyz to convert high-value medical assets into tradable digital certificates [3] - Ethereum serves as the underlying infrastructure, providing value anchoring for RWA and generating staking income to support treasury growth [3] - The company has implemented a "seven-fold downside protection mechanism" and a "three-tier income enhancement engine" to safeguard shareholder interests amid market volatility [3] Group 3: Market Response - Following the announcement of the first ETH purchase, the company's stock price surged over 91% within a month, with a market capitalization exceeding 15 billion HKD, making it a focal point in the Hong Kong medical sector [4] - Market analysis indicates that the dual-driven model of "crypto treasury + medical RWA" aligns with valuation logic seen in leading Ethereum companies in the US, while offering greater industrial synergy [4] - The company has established a strategic partnership with BGI Win-Win Fund to acquire quality innovative drug pipelines, enhancing the asset depth of the ivd.xyz exchange [4] Group 4: Compliance First - The company reiterates that all cryptocurrency transactions will be conducted on regulated platforms, seeking independent approval at the shareholder meeting to ensure transparency [5] - If the 3 billion HKD application is approved, the authorization will be valid for 36 months, allowing the board to execute the purchase plan in phases based on market conditions [5] - The innovative model of "Ethereum treasury + medical RWA" opens new pathways for asset allocation and value reassessment in the industry, with market anticipation on whether the company can become the "Hong Kong version of MicroStrategy" [5]